1. Home
  2. AKA vs CRDL Comparison

AKA vs CRDL Comparison

Compare AKA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo a.k.a. Brands Holding Corp.

AKA

a.k.a. Brands Holding Corp.

N/A

Current Price

$9.99

Market Cap

110.6M

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$0.97

Market Cap

120.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AKA
CRDL
Founded
2018
2017
Country
United States
Canada
Employees
1650
18
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.6M
120.9M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
AKA
CRDL
Price
$9.99
$0.97
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
★ $19.75
$8.55
AVG Volume (30 Days)
2.4K
★ 764.3K
Earning Date
11-04-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $600,208,000.00
N/A
Revenue This Year
$4.92
N/A
Revenue Next Year
$5.05
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$0.88
52 Week High
$14.39
$2.34

Technical Indicators

Market Signals
Indicator
AKA
CRDL
Relative Strength Index (RSI) 44.68 28.32
Support Level $8.54 $0.94
Resistance Level $11.41 $1.10
Average True Range (ATR) 0.35 0.06
MACD -0.02 0.00
Stochastic Oscillator 38.79 20.33

Price Performance

Historical Comparison
AKA
CRDL

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: